A new biotech company is opening in Gaithersburg, and is bringing with it 100 new jobs in the next three to five years.
The Centers for Disease Control and Prevention has awarded Emergent BioSolutions Inc. a $26 million contract to continue to supply a medical treatment to the government.
Across the globe, a collection of healthcare professionals gather around their computer screens in their respective offices in Beijing, Brussels, London, and Los Angeles. A skilled U.S.-based oncologist leads this virtual board in discussing a 38-year-old British patient with advanced lung cancer. Using virtual reality technology, the team is able to simultaneously review the patient’s entire disease profile, including her medical history and lifestyle, and see high-resolution pathology images and all sorts of other biological data.
The Maryland Tech Council (MTC) has announced the finalists for its 30th Anniversary Industry Awards Celebration. Winners will be revealed at a celebration on May 17, 2018 at The Hotel at The University of Maryland. The event, which draws more than 600 executives from the technology and life science communities, celebrates individuals and companies that have made a significant impact in their sectors.
Senti Biosciences, a startup that’s looking to make a new treatment that’s upending how we treat cancer, just raised $53 million.
“The first opportunity we have to delight or to upset a client is when they walk through the door either physically or virtually.”
Sounds like a tech executive, right? Jeff Bezos even? The Amazon boss often talks about delighting customers, after all, although until recently the ecommerce giant didn’t really have doors to physically walk through.
Emergent BioSolutions Inc. (NYSE:EBS) and Valneva SE (Euronext Paris:VLA) today announced the initiation of a Phase 1 clinical trial in the U.S. to evaluate the safety and immunogenicity of VLA1601, their vaccine candidate against Zika virus.
Apple is launching medical clinics for its employees in the latest attempt by a large tech company to address the U.S.’s growing healthcare problem. The new project, called AC Wellness, is launching sometime in the spring, according to its new website.
AstraZeneca has carved off six inflammation and autoimmune assets to create a new biotech, Viela Bio. The startup put together a $250 million series A round and a management team from its parent company to guide the mix of clinical and preclinical programs forward.
A Maryland bill that would make the state a national test case for controlling prescription drug costs has garnered broad legislative support in Annapolis but could put the state on a legal collision course with the pharmaceutical industry.